Massoud M, Armand J P, Ribrag V
Département de Médecine, Institut Gustave-Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France.
Eur J Cancer. 2004 Sep;40(13):1924-7. doi: 10.1016/j.ejca.2004.05.015.
Procarbazine (PCB) was developed in the 1960s and was rapidly recognised as an active agent in lymphoid malignancies. PCB was one of the four drugs combined in mechlorethamine, vincristine, PCB, prednisolone (MOPP), one of the first combination chemotherapy regimens to show that advanced-stage disease could be cured in humans. During the last few decades, comprehensive studies have clarified cellular pathways involved in the modes of action of PCB and its drug resistance mechanisms. However, late toxicities, especially secondary leukaemias and sterility, led to its withdrawal from combination regimens used to treat Hodgkin's lymphomas (HLs). PCB was recently reintroduced in dose-intensified regimens and yielded impressive results. These new regimens (bleomycin, etoposide, doxorubicin, vincristine, PCB, and prednisone (BEACOPP) or escalated BEACOPP) are now being investigated versus the classic ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or ABVD-like combination chemotherapy regimens in the treatment of HLs.
丙卡巴肼（PCB）于20世纪60年代研发出来，并迅速被认定为治疗淋巴系统恶性肿瘤的一种有效药物。PCB是氮芥、长春新碱、PCB、泼尼松（MOPP）联合使用的四种药物之一，MOPP是最早显示可治愈人类晚期疾病的联合化疗方案之一。在过去几十年里，全面的研究已经阐明了PCB作用模式及其耐药机制所涉及的细胞途径。然而，其晚期毒性，尤其是继发性白血病和不育症，导致它从用于治疗霍奇金淋巴瘤（HL）的联合方案中退出。最近，PCB被重新引入剂量强化方案，并取得了令人瞩目的效果。目前正在研究这些新方案（博来霉素、依托泊苷、阿霉素、长春新碱、PCB和泼尼松（BEACOPP）或强化BEACOPP）与经典的ABVD（阿霉素、博来霉素、长春花碱、达卡巴嗪）或类似ABVD的联合化疗方案在治疗HL方面的效果对比。
